The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
POD1UM-303/INTERAACT2 subgroup analyses and impact of delayed retifanlimab treatment on outcomes in patients with squamous cell carcinoma of the anal canal (SCAC).
 
Marwan Fakih
Honoraria - Amgen
Consulting or Advisory Role - Abbvie; Adagene; Bayer; BMS; Delcath Systems; Eisai; Entos; Janssen Research & Development; Merck; Microbial Machines; Mirati Therapeutics; Nouscom; Pfizer; Roche/Genentech; Taiho Pharmaceutical; Tempus; Totus Medicines
Research Funding - Agenus (Inst); Roche/Genentech (Inst); Verastem (Inst)
 
Rebecca Muirhead
No Relationships to Disclose
 
Aaron Scott
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
Consulting or Advisory Role - Exelixis; Pfizer; QED Therapeutics
Research Funding - Exelixis; Five Prime Therapeutics; Genentech; Incyte; Merck
Travel, Accommodations, Expenses - Exelixis; QED Therapeutics
 
Mohit Narang
Consulting or Advisory Role - Celgene
Speakers' Bureau - Celgene
 
Allen Cohn
Honoraria - Amgen
Consulting or Advisory Role - AADi; EMD Serono
Expert Testimony - Department of Justice
 
Marcia Cruz-Correa
Employment - Pan American Center for Oncology Trials
Stock and Other Ownership Interests - Pan American Center for Oncology Trials
Research Funding - Abbvie (Inst); BeiGene (Inst); Bristol-Myers Squibb/Celgene (Inst); Genentech/Roche (Inst); GENFIT (Inst); HUYA Bioscience International (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Regeneron (Inst); VMO (Inst)
Patents, Royalties, Other Intellectual Property - Licencing agreement with Johns Hopkins University on technology.
 
Mukul Gupta
No Relationships to Disclose
 
Sharadah Essapen
No Relationships to Disclose
 
Duncan Gilbert
No Relationships to Disclose
 
Toshihiro Kudo
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly Japan; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Daiichi Sankyo
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo/UCB Japan (Inst); Incyte Japan (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
 
David Lau
Consulting or Advisory Role - Takeda
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb
 
Maria Riesco Martinez
Consulting or Advisory Role - Ferrer
Speakers' Bureau - Servier/Pfizer
Research Funding - MSD Oncology (Inst)
Travel, Accommodations, Expenses - SERVIER
 
Maria Zampino
No Relationships to Disclose
 
Christelle De La Fouchardiere
Consulting or Advisory Role - Amgen; Astellas Pharma; BeiGene; Bristol-Myers Squibb; Daichi-Sankyo; Gilead Sciences; Jazz Pharmaceuticals; MSD Oncology; Pierre Fabre; Roche/Genentech; SERVIER; Takeda
Research Funding - Agenus (Inst); MSD (Inst); Pierre Fabre (Inst); Servier (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; MSD Oncology; Pierre Fabre; SERVIER
 
Jill Harrison
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Mark Jones
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Chuan Tian
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Atsuo Takashima
Honoraria - Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Amgen - Local PI (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst); Ono Pharmaceutical (Inst)
 
Jaume Capdevila
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Eisai; Esteve; Exelixis; Ipsen; Isotopen Technologien; Lilly; Merck Serono; Novartis; Pfizer; Roche/Genentech; Sanofi
Speakers' Bureau - Bayer; Eisai; Esteve; Hutchison MediPharma; Ipsen; Isotopen Technologien; Lilly; Merck Serono; Novartis; Pfizer; Sanofi
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Eisai (Inst); Gilead Sciences (Inst); Ipsen (Inst); Ipsen (Inst); ITM Solucin (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Eisai; Gilead Sciences; Ipsen; Pfizer
 
Sheela Rao
Honoraria - Bayer; Incyte; Merck Serono; Servier (I)
Consulting or Advisory Role - AstraZeneca; Bayer; Nordic Bioscience
Speakers' Bureau - Incyte; Merck Serono; SERVIER; Takeda
Travel, Accommodations, Expenses - MSD Oncology; SERVIER